News

Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 Million". Dublin & King of Prussia, PA.


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 Million". Dublin & King of Prussia, PA.

 

19/09/2017

Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing of its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share. In addition, Nabriva Therapeutics has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,411,764 ordinary shares at the public offering price, less the underwriting discounts and commissions. All of the ordinary shares in the offering are to be sold by Nabriva Therapeutics.

The offering is expected to close on or about September 22, 2017, subject to customary closing conditions. Morgan Stanley and BofA Merrill Lynch are acting as joint book-running managers and SunTrust Robinson Humphrey, Needham & Company and Wedbush PacGrow are acting as co-managers for the offering.

The public offering is being made pursuant to a shelf registration statement, including a prospectus, on Form S-3 that was filed by Nabriva Therapeutics with the Securities and Exchange Commission (“SEC”) and was declared effective on August 10, 2017. A final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained by contacting Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or BofA Merrill Lynch, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, e-mail: dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy Nabriva Therapeutics’ ordinary shares, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Offers will be made only by means of a prospectus supplement and the accompanying prospectus, forming a part of the registration statement. 


About Nabriva Therapeutics plc


Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics.


http://www.life-sciences-europe.com/news/nabriva-announces-pricing-80m-therapeutics-plc-nasdaq-nbrv-2001-111443.html

© Catalyst Innovation Portal 2019